

Tranlycypromin

Gerd Laux, Wasserburg, und Sven Ulrich, Osterweddingen

Literatur

- Amsterdam JD, Berwisch NJ. High dose tranlycypromine therapy for refractory depression. *Pharmacopsychiatry* 1989;22:21–5.
- Angheliescu I. Monoaminoxidase-Hemmstoffe. In: Bauer M, Berghöfer A, Adli M (Hrsg.). *Akute und therapieresistente Depressionen*. 2. Auflage. Heidelberg: Springer, 2005:206–16.
- Ashford JW, Ford CV. Use of MAO-inhibitors in elderly patients. *Am J Psychiatry* 1979;136:1466–7.
- Askar A, Treptow H. Biogene Amine in Obst. In: Beutling DM (Hrsg.). *Biogene Amine in der Ernährung*. Berlin, Heidelberg, New York: Springer, 1996:154–6.
- Arznei-Telegramm. Behandlung der hypertensiven Krise 1999;1:2–5.
- Baker GB, Urichuk LJ, McKenna KF, Kennedy SH. Metabolism of monoamine oxidase inhibitors. *Cell Mol Neurobiol* 1999;19:411–26.
- Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Gilman AG, Goodman LS, Gilman A (eds.). *The pharmacological basis of therapeutics*. 6th edition. New York: Macmillan, 1980:391–447.
- Barker WA, Eccleston D. The treatment of chronic depression: An illustrative case. *Br J Psychiatry* 1984;144:317–9.
- Barklage NE, Jefferson JW, Margolis D. Do monoamine oxidase inhibitors alter carbamazepine blood levels? *J Clin Psychiatry* 1992;53:258.
- Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. *Pharmacopsychiatry* 2004;37:243–65.
- Beckmann H, Laux G. Aktuelle Therapie mit MAO-Hemmern. *Krankenhauspsychiatrie* 1991;2:201–2.
- Berlin I, Zimmer R, Cournot A, Payan C, et al. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranlycypromine treatment in healthy volunteers. *Clin Pharmacol Ther* 1989;46:344–51.
- Biek PR. Interaktionen. In: Riederer P, Laux G, Pöldinger W (Hrsg.). *Neuro-Psychopharmaka*. Ein Therapiehandbuch. Band 3: Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer. Wien, New York: Springer 2002:518–38.
- Birkenhäger TK, Van den Broek WW, Mulder PG, Bruijn JA, et al. Efficacy and tolerability of tranlycypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. *J Clin Psychiatry* 2004;65:1505–10.
- Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. *Br J Psychiatry* 1967;113:349–65.
- Blume H, Potthast H, Mutschler E, Spahn-Languth H. Vergleichende Bioverfügbarkeitsstudie von Jatrosom N und Parnate vs. Tranlycypromin-Trinklösung: Abschlussbericht. Zentrallaboratorium Deutscher Apotheker, Eschborn und Pharmakologisches Institut für Naturwissenschaftler, Frankfurt am Main, 1994, unveröffentlichte Daten der esparma GmbH.
- Boakes AJ, Laurence DR, Teoh PC, Barar FSK, et al. Interactions between sympathomimetic amines and antidepressant agents in man. *BMJ* 1973;1:311–5.
- Briggs NC, Jefferson JW, Koenecke FH. Tranlycypromine addiction: a case report and review. *J Clin Psychiatry* 1990;51:426–9.
- Brown C, Taniguchi G, Yip K. The monoamine oxidase inhibitor-tyramine interaction. *J Clin Pharmacol* 1989;29:529–32.
- Brubacher JR, Hoffman RS, Lurin MJ. Serotonin syndrome from venlafaxine-tranlycypromine interaction. *Vet Hum Toxicol* 1996;38:358–61.
- Bschor T, Bauer M. Therapieresistente Depressionen. In: Lenke MR (Hrsg.). *Affektive Störungen*. Stuttgart, New York: Thieme, 2004:101–15.
- Caille D, Bergis OE, Fankhauser C, Gardes A, et al. Befloxadone, a new reversible and selective monoamine oxidase-A inhibitor II: Pharmacological profile. *J Pharmacol Exp Ther* 1996;277:265–77.
- Chen B, Wang JF, Sun X, Young LT. Regulation of GAP-43 expression by chronic desipramine treatment in rat cultured hippocampal cells. *Biol Psychiatry* 2003;15:530–7.
- Clemons WE, Makela E, Young J. Concomitant use of modafenil and tranlycypromine in a patient with narcolepsy: a case report. *Sleep Med* 2004;5:509–11.
- Console AD. Controlling MAO inhibitor hypotension. *Am J Psychiatry* 1964;120:709–11.
- Coutts RT, Rao TS, Baker GB, Micetich G, et al. Neurochemical and neuropharmacological properties of 4-fluorotranlycypromine. *Cell Mol Neurobiol* 1987;7:271–90.
- Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranlycypromine. *Arch Gen Psychiatry* 1988;45:111–9.
- Dechant KL, Clissold SP. Paroxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. *Drugs* 1991;41:225–53.
- Degner D, Grohmann R, Kropp S, Rüter E, et al. Severe adverse drug reactions of antidepressants: Results of the German multicenter drug surveillance program AMSP. *Pharmacopsychiatry* 2004;37(Suppl 1):39–45.
- Dilsaver SC, Del Medico VJ, Quadri A, Jaekle RS. Pharmacological responsiveness of winter depression. *Psychopharmacol Bull* 1990;26:303–9.
- Dross A, Wittkowski R. Biogene Amine in Wein. In: Beutling DM (Hrsg.). *Biogene Amine in der Ernährung*. Berlin, Heidelberg, New York: Springer, 1996:160–7.
- Edmondson DE, Mattevi A, Binda C, Li M, et al. Structure and mechanism of monoamine oxidase. *Curr Med Chem* 2004;11:1983–93.
- El-Ganzouri AR, Ivankovich AD, Braverman B, McCarthy R. Monoamine oxidase inhibitors: should they be discontinued preoperatively? *Anesth Analg* 1985;64:592–6.
- Erfurth A, Schmauß M. Monoaminoxidase-Hemmer in der Behandlung von Zwangserkrankungen. *Nervenarzt* 1993;64:70–2.
- Fahn S, Chouinard S. Experience with tranlycypromine in early Parkinson's disease. *J Neural Transm* 1998;52(Suppl):49–61.
- Feighner JP, Boyer WF, Tyler DL, Neborsky R. Adverse consequences of fluoxetine-MAOI combination therapy. *J Clin Psychiatry* 1990;51:222–5.
- Feighner JP, Herbstein J, Damlouji N. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. *J Clin Psychiatry* 1985;46:206–9.
- Ferrer A, Artigas F. Effects of single and chronic treatment with tranlycypromine on extracellular serotonin in rat brain. *Eur J Pharmacol* 1994;263:227–34.
- Fritz RR, Malek-Ahmadi P, Rose RM, Denny RM, et al. Tranlycypromine lowers human platelet MAO B activity but not concentration. *Biol Psychiatry* 1993;18:685–94.
- Gardner DM, Shulman KI, Walker SE, Tailor SAN. The making of a user friendly MAOI diet. *J Clin Psychiatry* 1996;57:99–104.
- Gentil V, Alevizos B, Lader M. Effects of single doses of tranlycypromine on platelet MAO and amine uptake in normal subjects. *Biochem Pharmacol* 1978;27:1197–201.

Prof. Dr. med. Gerd Laux, Bezirksklinikum Gabersee, Fachklinikum für Psychiatrie, Psychotherapie, Psychosomatische Medizin und Neurologie, 83512 Wasserburg am Inn, E-Mail: g.laux.bzk-gabersee@t-online.de
Priv.-Doz. Dr. Sven Ulrich, Leiter Abt. Arzneimittelsicherheit/Arzneimittelinformation, esparma GmbH, Lange Göhren 3, 39171 Osterweddingen, E-Mail: s.ulrich@esparma.de

42. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. *Br J Anaesth* 2005;95:434–41.
43. Gnanadesigan N, Espinoza RT, Smith R, Israel M, et al. Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected? *J Am Med Dir Assoc* 2005;6:265–9.
44. Gociniak HT. Wechsel von Tranylcypromin auf Moclobemid. *Psychopharmakother* 1997;4:106.
45. Graham PM. Combined mianserin and tranylcypromine. *Br J Psychiatry* 1988;153:415–7.
46. Greenshaw AJ, Nazarali AJ, Rao TS, Baker GB, et al. Chronic tranylcypromine treatment induces functional alpha-2-adrenoceptor down-regulation in rats. *Eur J Pharmacol* 1988;154: 67–72.
47. Greenshaw AJ, Rao TS, Nazarali AJ, Baker GB, et al. Chronic effects of tranylcypromine and 4-fluorotranlylcypromine on regional brain monoamine metabolism in rats: a comparison with chlorgyline. *Biol Psychiatry* 1989;25: 1014–20.
48. Gutze BH, Baxter LR jr. Refractory depression treated with high doses of a monoamine oxidase inhibitor. *J Clin Psychiatry* 1987;48: 31–2.
49. Haase HJ, Buhr HJ. Untersuchungen zur Verträglichkeit des Antidepressivums Jatrosom. *Med Welt* 1973;24:221–4.
50. Halle MT, Dilsaver SC. Tranylcypromine withdrawal phenomena. *J Psychiatry Neurosci* 1993;18:49–50.
51. Hampson DR, Baker GB, Coutts R. A comparison of the neurochemical properties of the stereoisomers of tranylcypromine in the central nervous system. *Cell Molec Biol* 1986;32: 595–9.
52. Harms HH, de Reus R, Pootjes YG, Rooze HA. Successful treatment of an elderly woman after stubborn resistance. *Ned Tijdschr Geneesk* 2000;144:201–3.
53. Heinze G, Rossel L, Gabeli I, Galeeano-Munoz J, et al. Double-blind comparison of moclobemide and tranylcypromine in depression. *Pharmacopsychiatry* 1993;26:240–5.
54. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. *BMJ* 1995;310:221–4.
55. Himmelhoch JM, Detre T, Kupfer DJ, Schwartzburg M, et al. Treatment of previously intractable depressions with tranylcypromine and lithium. *J Nerv Ment Dis* 1972;155:216–20.
56. Hirsch MS, Walter RM, Hasterlik RJ. Subarachnoid hemorrhage following ephedrine and MAOI. *J Am Med Assoc* 1965;194:201.
57. Hurst WJ, Toomey PB. HPLC determination of four biogenic amines in chocolate. *Analyst* 1981;106:394–402.
58. Jacobsen FM. Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study. *J Clin Psychiatry* 1990;51:298–302.
59. Jenike MA. The use of monoamine oxidase inhibitors in the treatment of elderly, depressed patients. *J Am Geriatr Soc* 1984;32:571–5.
60. Jenike MA. Monoamine oxidase inhibitors as treatment for depressed patients with primary degenerative dementia (Alzheimer's disease). *Am J Psychiatry* 1985;142:763–4.
61. Joffe RT. Tranylcypromine in recurrent brief depression: two case reports. *Int Clin Psychopharmacol* 1996;11:287–8.
62. Joffe RT, Post RM, Uhde TW. Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine. *Arch Gen Psychiatry* 1985;42:738.
63. Kahn D, Silver JM, Opler LA. The safety of switching rapidly from tricyclic antidepressants to monoamine oxidase inhibitors. *J Clin Psychopharmacol* 1989;9:198–202.
64. Karki SD, Masood GR. Combination risperidone and SSRI-induced serotonin syndrome. *Ann Pharmacother* 2003;37:388–91.
65. Kaye CM, Haddock RE, Langley PF, Mellows G, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. *Acta Psychiatr Scand* 1989;350(Suppl):60–75.
66. Keck PE, Carter WP, Nierenberg AA, Cooper TB, et al. Acute cardiovascular effects of tranylcypromine: correlation with plasma drug, metabolite, norepinephrine and MHPG levels. *J Clin Psychiatry* 1991;52:250–4.
67. Kelvin A, Hakansson S. Comparative acute toxicity of paroxetine and other antidepressants. *Acta Psychiatr Scand* 1989;80(Suppl): 31–3.
68. Ketter TA, Post RM, Parekh PI, Worthington K. Addition of monoamine oxidase inhibitors to carbamazepine: Preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. *J Clin Psychiatry* 1995;56:471–5.
69. Kielwein G. Vorkommen von biogenen Aminen in Käse. In: Beutling DM (Hrsg.). *Biogene Amine in der Ernährung*. Berlin, Heidelberg, New York: Springer, 1996:106–31.
70. Kuß HJ, Ackenheil M. No change of amitriptyline concentration by comedication of tranylcypromine. *Pharmacopsychiatry* 2005;38:56.
71. Laux G, Becker T, Müller U. Indikationen (von Tranylcypromin). In: Riederer P, Laux G, Pödlinger W (Hrsg.). *Neuro-Psychopharmaka. Ein Therapiehandbuch. Band 3: Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer*. Wien, New York: Springer, 2002: 489–507.
72. Lemberger P, Scherbaum W. Anästhesie bei Patienten mit Psychopharmaka-Dauertherapie. *Anästhesi Intensivmed* 1992;33:124–31.
73. Lieb J, Collins C. Treatment of delusional depression with tranylcypromine. *J Nerv Ment Dis* 1978;166:805–8.
74. Lippman SB, Nash K. Monoamine oxidase inhibitor update. Potential adverse food and drug interactions. *Drug Saf* 1990;5:195–204.
75. Lydiard RB, White D, Harvey B, Taylor A. Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine. *J Clin Psychopharmacol* 1987;7:360.
76. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. *J Neurosci* 2000;20:9104–10.
77. Mallinger AG, Himmelhoch JM, Thase ME, Edwards DJ, et al. Plasma tranylcypromine: relationship to pharmacokinetic variables and clinical antidepressant actions. *J Clin Psychopharmacol* 1990;10:176–83.
78. Malyszko J, Urano T, Serizawa K, et al. Serotonergic measures in blood and brain and their correlations in rats treated with tranylcypromine, a monoamine oxidase inhibitor. *Jpn J Physiol* 1993;43:613–26.
79. Maki Y, Inoue T, Izumi T, et al. Monoamine oxidase inhibitors reduce conditioned fear stress-induced freezing behavior in rats. *Eur J Pharmacol* 2000;406:411–8.
80. Mann JJ. Loss of antidepressant effect with long-term monoamine oxidase inhibitor treatment without loss of monoamine oxidase inhibition. *J Clin Psychopharmacol* 1983;3: 363–6.
81. Mittmann N, Herrmann N, Shulman KI, Silver IL, et al. The effectiveness of antidepressants in elderly depressed outpatients: a prospective case series study. *J Clin Psychiatry* 1999;60: 690–7.
82. Monaco JT, Delaplaine RP. Tranylcypromine with ECT. *Am J Psychiatry* 1964;120:1003.
83. Murphy DL, Aulakh CS, Garrick NA, Sunderland T. MAO-inhibitors as antidepressants: implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In: Meltzer HY (Hrsg.). *Psychopharmacology: the third generation of progress*. New York: Raven, 1987.
84. Nierenberg AA, Keck PE Jr. Management of monoamine oxidase inhibitor-associated insomnia with trazodone. *J Clin Psychopharmacol* 1989;9:42–5.
85. Nolen WA. Tranylcypromine in depression resistant to cyclic antidepressants. *Progr Neuropsychopharmacol Biol Psychiatry* 1989;13: 155–8.
86. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. II. MAO inhibitors in depression resistant to cyclic antidepressants: Two controlled cross-over studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. *Acta Psychiatr Scand* 1988;78: 668–83.
87. O'Brien S, McKeon P, O'Regan M, O'Flaherty, et al. Blood pressure effects of tranylcypromine when prescribed singly and in combination with amitriptyline. *J Clin Psychopharmacol* 1992;12:104–9.
88. Oostervink F, Bouvy PF, Touw DJ. Elderly patients, classical monoamine oxidase inhibitors and intercurrent somatic diseases. *Ned Tijdschr Geneesk* 2003;147: 1937–40.
89. Otte W, Birkenhager TK, Van den Broek WW. Fatal interaction between tranylcypromine and imipramine. *Eur Psychiatry* 2003;18: 264–5.
90. Paetsch PR, Greenshaw AJ. Effects of chronic antidepressant treatment on beta-adrenoceptor subtype binding in the rat cerebral cortex and cerebellum. *Mol Chem Neuropathol* 1993;20: 21–31.
91. Pearlman C. High dose tranylcypromine in refractory depression. *J Clin Psychiatry* 1987;48: 424–5.

92. Pierre JM, Gitlin MJ. Bupropion-tranylcypromine combination for treatment-refractory depression. *J Clin Psychiatry* 2000;61:450–1.
93. Pisani F, Oteri G, Costa C, Di Raimondo G, et al. Effects of psychotropic drugs on seizure threshold. *Drug Saf* 2002;25:91–110.
94. Pope HG, Jonas JM, Hudson JI, Kafka MP. Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan. *Am J Psychiatry* 1985;142:491–2.
95. Porsolt RD. Behavioural despair. In: Enna SJ, Malick JB, Richelson E (Hrsg.). *Antidepressants: Neurochemical behaviour and clinical perspectives*. New York: Raven, 1981:121–39.
96. Price LH, Charney DS, Heninger GR. Efficacy of lithium-tranylcypromine treatment in refractory depression. *Am J Psychiatry* 1985;142:619–23.
97. Rabkin J, Quitkin F, Harrison W, Tricamo E, et al. Adverse reactions to monoamine oxidase inhibitors. Part I. a comparative study. *J Clin Psychopharmacol* 1984;4:270–8.
98. Razani J, White KL, White JW, et al. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. *Arch Gen Psychiatry* 1983;40:657–61.
99. Reggev A, Vollhardt BR. Bradycardia induced by an interaction between phenelzine and beta blockers. *Psychosomatics* 1989;30:106–8.
100. Riederer P, Lachmayer L, Laux G. Clinical application of MAO-inhibitors. *Curr Med Chem* 2004;11:2033–43.
101. Rimpel J, Gastpar M. *Psychopharmakakombinationen bei Angst, Phobie und Zwangserkrankungen*. Münch Med Wochenschr 1992;134:805–7.
102. Robinson DS. High-dose monoamine oxidase inhibitor therapy. *J Am Med Assoc* 1983;250:2212.
103. Rossel L, Moll E. Moclobemide versus tranylcypromine in the treatment of depression. *Acta Psychiatr Scand* 1990;360(Suppl):61–2.
104. Russel T, Joffe MD. Afternoon fatigue and somnolence associated with tranylcypromine treatment. *J Clin Psychiatry* 1990;51:192–3.
105. Salsali M, Holt A, Baker GB. Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. *Cell Mol Neurobiol* 2004;24:63–76.
106. Schmauß M. Hochdosierte Tranylcyprominbehandlung therapieresistenter Depressionen. *Nervenarzt* 1996;67:390–3.
107. Schmauß M, Kapfhammer HP, Meyr P, Hoff P. Combined MAO-inhibitor and tri-(tetra)cyclic antidepressant treatment in therapy-resistant depression. *Prog Neuropsychopharmacol Biol Psychiatry* 1988;12:523–32.
108. Sherry RL, Rauw G, McKenna KF, Paetsch PR, et al. Failure to detect amphetamine or 1-amino-3-phenylpropane in humans or rats receiving the MAO inhibitor tranylcypromine. *J Affect Disord* 2000;61:23–9.
109. Silverman RB. Mechanism of inactivation of MAO by trans-2-phenylcyclopropylamine and the structure of the enzyme-inactivator adduct. *Biol Chem* 1983;258:14766–9.
110. Simonson M. Controlling MAO inhibitor hypotension. *Am J Psychiatry* 1964;120:1118–9.
111. Smith DF. Role of monoamines in behavior of reserpinized rats given tranylcypromine stereoisomers. *J Neur Trans* 1981;50:193–200.
112. Smith MS, Muir H, Hall R. Perioperative management of drug therapy: clinical considerations. *Drugs* 1996;51:238–59.
113. Sovner R. Amphetamine and tranylcypromine in treatment-resistant depression. *Biol Psychiatry* 1990;28:1011–2.
114. Sprung J, Distel D, Grass J, Bloomfield EL, et al. Cardiovascular collapse during anesthesia in a patient with preoperatively discontinued chronic MAO inhibitor therapy. *J Clin Anesth* 1996;8:662–5.
115. Stack CG, Rogers P, Linter SP. Monoamine oxidase inhibitors and anaesthesia: a review. *Br J Anaesth* 1988;60:222–7.
116. Stoll AL, Haura G. Tranylcypromine plus risperidone for treatment-refractory major depression. *J Clin Psychopharmacol* 2000;20:495–6.
117. Stout SC, Owens MJ, Nemeroff CB. Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. *J Pharmacol Exp Ther* 2002;300:1085–92.
118. Szelenyi A, Albrecht J. Tranylcypromine abuse associated with an isolated thrombocytopenia. *Pharmacopsychiatry* 1998;31:238–40.
119. Szuba MP, Hornig-Rohan M, Amsterdam JD. Rapid conversion from one monoamine oxidase inhibitor to another. *J Clin Psychiatry* 1997;58:307–10.
120. Taavitsainen P, Juvonen R, Pelkonen O. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. *Drug Metab Dispos* 2001;29:217–22.
121. Taylor BP, Quitkin FM, McGrath PJ, Stewart JW. Do antihypertensives make tranylcypromine safer? Three case reports. *J Clin Psychiatry* 2005;66:657–8.
122. Teicher MH, Cohen BM, Baldessarini RJ, Cole JO. Severe daytime somnolence in patients treated with an MAOI. *Am J Psychiatry* 1988;145:1552–6.
123. Thase ME, Frank E, Mallinger AG, Hamer T, et al. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. *J Clin Psychiatry* 1992;53:5–11.
124. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression, IV: A double-blind cross-over study of tranylcypromine for anergic bipolar depression. *Am J Psychiatry* 1992;149:195–8.
125. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. *Neuropsychopharmacology* 1995;12:185–219.
126. Thompson DS, Sweet RA, Marzula K, Peredes JC. Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient. *J Clin Psychopharmacol* 1997;17:322–3.
127. Tolksdorf W, Baier D, Dingemans J. Monoaminoxidase-Hemmstoffe und RIMA-Substanzen in der Anästhesie. *Anästh Intensivmed* 1992;33:175–85.
128. Tipton KF, Boyce S, O'Sullivan J, Davey GP, et al. Monoamine oxidases: certainties and uncertainties. *Curr Med Chem* 2004;11:1965–82.
129. Ulrich S, Pawelzik M, Göhring J. Pharmacovigilance of Jatrosom N (tranylcypromine). *Pharmacopsychiatry* 2005;38:65.
130. Van Den Berg CM, Blob LF, Kemper EM, Azzaro AJ. Tyramine pharmacokinetics and reduced bioavailability with food. *J Clin Pharmacol* 2003;43:604–9.
131. Versiani M, Mundim FD, Nardi AE, Liebowitz MR. Tranylcypromine in social phobia. *J Clin Psychopharmacol* 1988;8:279–83.
132. Vink J, Nolen WA, Verbraak M. Is Moclobemide bij therapieresistente depressie een alternatief voor tranylcypromine? *Tijdschr Psychiatr* 1994;36:639–46.
133. Volz HP, Faltus F, Magyar I, Möller HJ. Brofaromine in treatment-resistant depressed patients – a comparative trial versus tranylcypromine. *J Affect Disord* 1994;30:209–17.
134. Volz HP, Gleiter CH. Monoamine oxidase inhibitors: A perspective on their use in the elderly. *Drugs Aging* 1998;13:341–56.
135. Volz HP, Gleiter CH, Möller HJ. Monoaminoxidasehemmer in der Psychiatrie. *Nervenarzt* 1996;67:339–47.
136. Wager SG, Klein DF. Drug therapy strategies for treatment-resistant depression. *Psychopharmacol Bull* 1988;24:69–74.
137. Wells DG, Bjorksten AR. Monoamine oxidase inhibitors revisited. *Can J Anaesth* 1989;36:64–74.
138. Wen X, Wang JS, Neuvonen PJ, Backman JT. Isoniazide is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. *Eur J Clin Pharmacol* 2002;57:799–804.
139. White K, Pistole T, Boyd JL. Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: A pilot study. *Am J Psychiatry* 1980;137:1422–5.
140. White K, Razani J, Cadow B, Gelfand R, et al. Tranylcypromine vs. nortriptyline vs. placebo in depressed outpatients: A controlled trial. *Psychopharmacology* 1984;82:258–62.
141. White K, White J. Tranylcypromine: Patterns and predictors of response. *J Clin Psychiatry* 1986;47:380–2.
142. Youdim MB, Riederer P. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. *Neurology* 2004;63(Suppl 2):32–5.
143. Zimmer B, Daly F, Benjamin L. More on combination antidepressant therapy. *Arch Gen Psychiatry* 1984;41:527–8.